Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,691 matching trials from the live ClinicalTrials.gov search.
Filters: Scottsdale, Arizona Clear all
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

NCT00996957
View directory record Official record
Conditions
Advanced Solid Tumors, Multiple Myeloma
Interventions
ACE-041
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

NCT02552212
View directory record Official record
Conditions
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01473381
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of GW679769 In Major Depressive Disorder

NCT00102492
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 31, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

NCT03955471
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

NCT03934814
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
TJ011133, Pembrolizumab, Rituximab
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

NCT01519804
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
34
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 31, 2026, 10:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112
View directory record Official record
Conditions
Refractory Melanoma
Interventions
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
Biological · Procedure · Drug
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 10:14 AM EDT
Active, not recruiting Not applicable Interventional

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

NCT03947619
View directory record Official record
Conditions
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Interventions
Impella CP® placement prior to reperfusion with Primary PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 31, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Oral Treprostinil in Digital Ulcers

NCT00848107
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 31, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02374099
View directory record Official record
Conditions
Breast Neoplasms
Interventions
CC-486, Fulvestrant
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

NCT03569293
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821
View directory record Official record
Conditions
Lymphoma
Interventions
epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
162
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer

NCT00003170
View directory record Official record
Conditions
Cancer
Interventions
glutamine, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
17
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

Comparison of the Effects of Two Spinal Cord Stimulation (SCS) Therapies on Subject Reported Pain (BENEFIT-02)

NCT03594266
View directory record Official record
Conditions
Chronic Low Back Pain, Chronic Leg Pain
Interventions
Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components, Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Peoria, Arizona • Scottsdale, Arizona • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 31, 2026, 10:14 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

NCT05601219
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ADA-011, PD(L)-1 inhibitor
Drug
Lead sponsor
Adanate, Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Scottsdale, Arizona • Orlando, Florida • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 31, 2026, 10:14 AM EDT
Terminated Phase 3 Interventional Results available

Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs

NCT00477230
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Endoscopic Ablation System, Standard Anti-arrhythmic Drug (AAD) Therapy
Device · Drug
Lead sponsor
CardioFocus
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 31, 2026, 10:14 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT07906665
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NI112, Placebo
Drug
Lead sponsor
Sachi Bioworks Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

NCT02718300
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Parsaclisib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 31, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

NCT02178956
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
BBI608, Paclitaxel, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Scottsdale, Arizona • Denver, Colorado • Goshen, Indiana + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 31, 2026, 10:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 10:14 AM EDT
Active, not recruiting No phase listed Observational

The Syn-Sleep Study

NCT05757206
View directory record Official record
Conditions
REM Sleep Behavior Disorder (iRBD)
Interventions
Syn-One Test
Diagnostic Test
Lead sponsor
CND Life Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 31, 2026, 10:14 AM EDT
Recruiting Not applicable Interventional

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

NCT06910306
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliomas
Interventions
Device :DaRT seeds
Device
Lead sponsor
Alpha Tau Medical LTD.
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 31, 2026, 10:14 AM EDT